The Candidate, Kathryn A. Cunningham, has been supported by a K02 (DA00260) from 5/1/96-4/30/05, a period marked by a number of career, research and mentoring successes. The PI is the Chauncey Leake Distinguished Professor in Pharmacology at the University of Texas Medical Branch (UTMB), is the Director of the UTMB Center for Addiction Research and Director of a NIDA training grant. Continuously funded by NIDA, she has been active in drug abuse research for 20 years and has made important contributions to the field in areas related to both the neurobiology of abused drugs and addictive processes. Her current research endeavors are focused on gaining a more complete understanding of the neural basis underlying the effects of cocaine and the substituted amphetamine 3,4-methylenedioxymethamphetamine (MDMA) which share actions to stimulate brain serotonin (5-HT) systems. Serotonin is involved in the etiology of psychotic and affective disorders (e.g., anxiety, depression) which are often experienced by drug users and the 5-HT system is an important target in the quest for medications for addiction. Accordingly, the research goals of the present application for a K05 will include tests of the following hypotheses: (1) the oppositional roles of 5-HT2A receptors (5- HT2AR) and 5-HT2CR to control the cellular and behavioral responses to cocaine occur within the mesocorticoaccumbens circuit; models of addictive behavior (conditioned place preference, self-administration), high resolution immunohistochemistry and localized microinjection of receptor-specific ligands and virally-mediated genes are being employed [DA 06511]; (2) the in vivo effects of MDMA are mediated by both concurrent and sequential activation of 5- HT and dopamine systems; behavioral pharmacological and molecular biological tools are being used to dissect the roles of these systems [DA 13595]; (3) vulnerability to drug self-administration is related to the protein profile of the chronic stress response in brain; proteomics approaches are being employed to assess this hypothesis [DA 0 16905]. With the current proposal for a K05, these research goals will be supplemented by the development of expertise and the application of emerging proteomics technologies to characterize key proteins and protein signatures associated with exposure to abused drugs in animal models of addiction and in vulnerability to drug dependence. A related long term goal is to expand our program via collaborative interactions to include translational investigations in the identification of serum biomarkers of addiction phenotypes to allow detection of the disease at earliest stage of progression (diagnostic) and biomarkers of the disease stage in an addict to foretell disease and treatment outcome (prognostic). The mentoring goals will be to provide guidance for junior scientists in transdisciplinary investigations in addiction research, to continue to administer the NIDA training grant [DA07287] and to develop curricula for the training of health care professionals in the sciencebased treatment of drug dependence. The leadership goals include creation and direction of the University of Texas Medical Branch (UTMB) Center for Addiction Research, continued involvement in research initiatives in drug abuse at UTMB, in Texas and the U.S., and active participation in the leadership of the College on Problems of Drug Dependence.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Scientist Award (K05)
Project #
5K05DA020087-02
Application #
7098795
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Lynch, Minda
Project Start
2005-08-01
Project End
2010-07-31
Budget Start
2006-08-01
Budget End
2007-07-31
Support Year
2
Fiscal Year
2006
Total Cost
$117,145
Indirect Cost
Name
University of Texas Medical Br Galveston
Department
Pharmacology
Type
Schools of Medicine
DUNS #
800771149
City
Galveston
State
TX
Country
United States
Zip Code
77555
Felsing, Daniel E; Anastasio, Noelle C; Miszkiel, Joanna M et al. (2018) Biophysical validation of serotonin 5-HT2A and 5-HT2C receptor interaction. PLoS One 13:e0203137
Gilbertson, Scott R; Chen, Ying-Chu; Soto, Claudia A et al. (2018) Synthesis and activity of functionalizable derivatives of the serotonin (5-HT) 5-HT2A receptor (5-HT2AR) antagonist M100907. Bioorg Med Chem Lett 28:1381-1385
Price, Amanda E; Anastasio, Noelle C; Stutz, Sonja J et al. (2018) Serotonin 5-HT2C Receptor Activation Suppresses Binge Intake and the Reinforcing and Motivational Properties of High-Fat Food. Front Pharmacol 9:821
Soto, Claudia A; Shashack, Matthew J; Fox, Robert G et al. (2018) Novel Bivalent 5-HT2A Receptor Antagonists Exhibit High Affinity and Potency in Vitro and Efficacy in Vivo. ACS Chem Neurosci 9:514-521
Miller, William R; Fox, Robert G; Stutz, Sonja J et al. (2018) PPAR? agonism attenuates cocaine cue reactivity. Addict Biol 23:55-68
Simmler, Linda D; Anacker, Allison M J; Levin, Michael H et al. (2017) Blockade of the 5-HT transporter contributes to the behavioural, neuronal and molecular effects of cocaine. Br J Pharmacol 174:2716-2738
Cortez, IbDanelo; Bulavin, Dmitry V; Wu, Ping et al. (2017) Aged dominant negative p38? MAPK mice are resistant to age-dependent decline in adult-neurogenesis and context discrimination fear conditioning. Behav Brain Res 322:212-222
Neelakantan, Harshini; Holliday, Erica D; Fox, Robert G et al. (2017) Lorcaserin Suppresses Oxycodone Self-Administration and Relapse Vulnerability in Rats. ACS Chem Neurosci 8:1065-1073
Gao, Yong; Yao, Ting; Deng, Zhuo et al. (2017) TrpC5 Mediates Acute Leptin and Serotonin Effects via Pomc Neurons. Cell Rep 18:583-592
Schmitz, Joy M; Green, Charles E; Hasan, Khader M et al. (2017) PPAR-gamma agonist pioglitazone modifies craving intensity and brain white matter integrity in patients with primary cocaine use disorder: a double-blind randomized controlled pilot trial. Addiction 112:1861-1868

Showing the most recent 10 out of 60 publications